Pharmacokinetic equivalence of Taxotere and SID530, a novel docetaxel formulation containing hydroxypropyl-beta-cyclodextrin in monkeys

Arzneimittel-Forschung/Drug Research

Volumn 62, Issue 6, 2012, Pages 280-284

  Kim, T K ^a,b   Yoo, H H ^c   Kim, E J ^b   Lee, B Y ^b   Park, J H ^a  

^a Seoul National University   (South Korea)

^b SK Chemicals   (South Korea)

^c Hanyang University   (South Korea)

Author keywords

bioequivalence; docetaxel; HP CD; LC MS MS; polysorbate 80

Indexed keywords

ANTINEOPLASTIC AGENT; DOCETAXEL; SID 530; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG FORMULATION; HAPLORHINI; LIQUID CHROMATOGRAPHY; MALE; MASS SPECTROMETRY; NONHUMAN; SINGLE DRUG DOSE;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AREA UNDER CURVE; BETA-CYCLODEXTRINS; CALIBRATION; CHEMISTRY, PHARMACEUTICAL; EXCIPIENTS; MACACA FASCICULARIS; MALE; REFERENCE STANDARDS; TANDEM MASS SPECTROMETRY; TAXOIDS; THERAPEUTIC EQUIVALENCY;

EID: 84862859461     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0032-1306305     Document Type: Article

References (21)

1. Clarke S J, Rivory L P. Clinical pharmacokinetics of docetaxel. Clin Pharmacokinet: 1999; 36 99 114 (Pubitemid 29121684)
2. Lyseng-Williamson K A, Fenton C. Docetaxel: a review of its use in metastatic breast cancer. Drugs: 2005; 65 2513 2531 (Pubitemid 41697318)
3. Michael A, Syrigos K, Pandha H. Prostate cancer chemotherapy in the era of targeted therapy. Prostate Cancer Prostatic Dis: 2009; 12 13 16
4. Gould S, Scott R C. 2-Hydroxypropyl-beta-cyclodextrin (HP-beta-CD): A toxicology review. Food Chem Toxicol: 2005; 43 1451 1459
5. Brewster M E, Loftsson T. Cyclodextrins as pharmaceutical solubilizers. Adv Drug Deliv Rev: 2007; 59 645 666 (Pubitemid 47299263)
6. Burris H A. Optimal use of docetaxel (T 235 axotere): maximizing its potential. Anticancer Drugs: 1996; 7 02 25 28 (Pubitemid 26275619)
7. Hennenfent K L, Govindan R. Novel formulations of taxanes: a review. Old wine in a new bottle? Ann Oncol: 2006; 17 735 749
8. ten Tije A J, Verweij J, Loos W J et al. Pharmacological effects of formulation vehicles: implications for cancer chemotherapy. Clin Pharmacokinet: 2003; 42 665 685 (Pubitemid 36936530)
9. Crispens C G Jr, Sorenson J R. Treatment of reticulum cell sarcoma in SJL/J mice with Tween 80. Anticancer Res: 1988; 8 1341 1343 (Pubitemid 19045925)
10. Loos W J, Baker S D, Verweij J et al. Clinical pharmacokinetics of unbound docetaxel: role of polysorbate 80 and serum proteins. Clin Pharmacol Ther: 2003; 74 364 371 (Pubitemid 37222857)
11. Fleuren H L, van Rossum J M. Nonlinear relationship between plasma and red 245 blood cell pharmacokinetics of chlorthalidone in man. J Pharmacokinet Biopharm: 1977; 5 359 375 (Pubitemid 8151030)
12. Hinderling P H. Red blood cells: a neglected compartment in pharmacokinetics and pharmacodynamics. Pharmacol Rev: 1997; 49 279 295 (Pubitemid 27414916)
13. Kurata D, Wilkinson G R. Erythrocyte uptake and plasma binding of diphenylhydantoin. Clin Pharmacol Ther: 1974; 16 02 355 362
14. Hinderling P H. Kinetics of partitioning and binding of digoxin and its analogues in the subcompartments of blood. J Pharm Sci: 1984; 73 1042 1053 (Pubitemid 14055833)
15. Musumeci T, Ventura C A, Giannone I et al. PLA/PLGA nanoparticles for sustained release of docetaxel. Int J Pharm: 2006; 325 172 179 (Pubitemid 44573694)
16. Yang M, Ding Y, Zhang L et al. Novel thermosensitive polymeric micelles for docetaxel delivery. J Biomed Mater Res A: 2007; 81 847 857
17. Du W, Hong L, Yao T et al. Synthesis and evaluation of water-soluble docetaxel prodrugs-docetaxel esters of malic acid. Bioorg Med Chem: 2007; 15 6323 6330 (Pubitemid 47088946)
18. Gao K, Sun J, Liu K et al. Preparation and characterization of a submicron lipid emulsion of docetaxel: submicron lipid emulsion of docetaxel. Drug Dev Ind Pharm: 2008; 34 1227 1237
19. Zhao L, Wei Y M, Zhong X D et al. PK and tissue distribution of docetaxel in rabbits after i. v. administration of liposomal and injectable formulations. J Pharm Biomed Anal: 2009; 49 989 996
20. Quaglia F, Ostacolo L, Mazzaglia A et al. The intracellular effects of non-ionic amphiphilic cyclodextrin nanoparticles in the delivery of anticancer drugs. Biomaterials: 2009; 30 374 382
21. Huang X X, Zhou C L, Wang H et al. Pharmacokinetics, efficacy, and safety evaluation of docetaxel/hydroxypropyl sulfobutyl-β-cyclodextrin inclusion complex. AAPS PharmSciTech: 2011; 12 665 672